Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches.[4]
History and developmentEdit
Nizatidine was developed by Eli Lilly, and was first marketed in 1988.[2] It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to Reliant Pharmaceuticals.[5] Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the U.S. Food and Drug Administration (FDA).[6] However, a year later, they sold rights of the Axid Oral Solution (including the issued patent[7] protecting the product) to Braintree Laboratories.[8]
Society and cultureEdit
Brand namesEdit
Brand names include Tazac and Axid.
ReferencesEdit
^Romero M, Franzosi MG (1989). "[Nizatidine]". Medicina (in Italian). 9 (1): 93–96. PMID 2567957.
^Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 44. ISBN9783527607495.
^ ab"Nizatidine". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf. 25 January 2018. PMID 31643707. NBK548387. Retrieved 19 March 2020.
^. Encyclopedia.com. 7 September 2000. Archived from the original on May 26, 2008.
^"Reliant Pharmaceuticals to Launch AxidŽ Oral Solution". Reliant Pharmaceuticals, LLC. 26 July 2004.
^US 6930119, Bobotas G, Fawzy AA, "Liquid pharmaceutical composition", issued 24 June 2005, assigned to Reliant Pharmaceuticals, LLC
^. Reliant Pharmaceuticals, LLC. Archived from the original on August 14, 2007.
nizatidine, histamine, receptor, antagonist, that, inhibits, stomach, acid, production, commonly, used, treatment, peptic, ulcer, disease, gastroesophageal, reflux, disease, clinical, datatrade, namesaxid, tazacahfs, drugs, commonographmedlineplusa694030licens. Nizatidine is a histamine H2 receptor antagonist that inhibits stomach acid production and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease 1 NizatidineClinical dataTrade namesAxid TazacAHFS Drugs comMonographMedlinePlusa694030License dataUS DailyMed Nizatidine US FDA NizatidinePregnancycategoryAU B3Routes ofadministrationBy mouthATC codeA02BA04 WHO Legal statusLegal statusAU S4 Prescription only UK POM Prescription only US OTC Rx onlyPharmacokinetic dataBioavailability gt 70 Protein binding35 MetabolismLiverElimination half life1 2 hoursExcretionKidneyIdentifiersIUPAC name E 1 N 2 2 dimethylamino methyl 1 3 thiazol 4 yl methylsulfanyl ethyl 1 N methyl 2 nitroethene 1 1 diamineCAS Number76963 41 2 YPubChem CID3033637IUPHAR BPS7248DrugBankDB00585 YChemSpider2298266 YUNIIP41PML4GHRKEGGD00440 YChEBICHEBI 7601 NChEMBLChEMBL653 YCompTox Dashboard EPA DTXSID5023376ECHA InfoCard100 155 683Chemical and physical dataFormulaC 12H 21N 5O 2S 2Molar mass331 45 g mol 13D model JSmol Interactive imageSMILES O N O C C NC NCCSCc1nc sc1 CN C CInChI InChI 1S C12H21N5O2S2 c1 13 11 6 17 18 19 14 4 5 20 8 10 9 21 12 15 10 7 16 2 3 h6 9 13 14H 4 5 7 8H2 1 3H3 b11 6 YKey SGXXNSQHWDMGGP IZZDOVSWSA N Y N Y what is this verify It was patented in 1980 and approved for medical use in 1988 2 3 It was developed by Eli Lilly Contents 1 Medical use 2 Adverse effects 3 History and development 4 Society and culture 4 1 Brand names 5 ReferencesMedical use EditMain article H2 antagonist Nizatidine is used to treat duodenal ulcers gastric ulcers and gastroesophageal reflux disease GERD GORD and to prevent stress ulcers 4 Adverse effects EditSide effects are uncommon usually minor and include diarrhea constipation fatigue drowsiness headache and muscle aches 4 History and development EditNizatidine was developed by Eli Lilly and was first marketed in 1988 2 It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine In September 2000 Eli Lilly announced they would sell the sales and marketing rights for Axid to Reliant Pharmaceuticals 5 Subsequently Reliant developed the oral solution of Axid marketing this in 2004 after gaining approval from the U S Food and Drug Administration FDA 6 However a year later they sold rights of the Axid Oral Solution including the issued patent 7 protecting the product to Braintree Laboratories 8 Society and culture EditBrand names Edit Brand names include Tazac and Axid References Edit Romero M Franzosi MG 1989 Nizatidine Medicina in Italian 9 1 93 96 PMID 2567957 a b Nizatidine FDA Approved Drugs U S Food and Drug Administration FDA Retrieved 20 March 2020 Fischer J Ganellin CR 2006 Analogue based Drug Discovery John Wiley amp Sons p 44 ISBN 9783527607495 a b Nizatidine LiverTox Clinical and Research Information on Drug Induced Liver Injury NCBI Bookshelf 25 January 2018 PMID 31643707 NBK548387 Retrieved 19 March 2020 Eli Lilly and Company and Reliant Pharmaceuticals Announce Agreement for U S Sales and Marketing Rights to Axid R Encyclopedia com 7 September 2000 Archived from the original on May 26 2008 Reliant Pharmaceuticals to Launch AxidZ Oral Solution Reliant Pharmaceuticals LLC 26 July 2004 US 6930119 Bobotas G Fawzy AA Liquid pharmaceutical composition issued 24 June 2005 assigned to Reliant Pharmaceuticals LLC Reliant Pharmaceuticals Announces the Sale of Axid Oral Solution to Braintree Laboratories Reliant Pharmaceuticals LLC Archived from the original on August 14 2007 Portal nbsp Medicine Retrieved from https en wikipedia org w index php title Nizatidine amp oldid 1179000541, wikipedia, wiki, book, books, library,
